Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global GBM market. The report identifies the key trends shaping and driving the global GBM market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global GBM sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global GBM therapeutics market was valued at $370m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 2.4% to reach $449m by 2018. This low growth rate is primarily attributed to the patent expiry of Temodal/Temodar (temozolomide, TMZ) in Europe in 2009 and in the US in 2014. The entry of low cost generics in Europe in 2010 has led to a decrease in the market valuation. TMZ has been an established standard of care for newly diagnosed GBM patients since its approval in 2005 and has led to a considerable increase in the number of patients on chemotherapy. In addition, the late stage pipeline products including Avastin (bevacizumab), enzastaurin and cilengitide for GBM are not expected to significantly drive the market upon their launch as the clinical trial results have not shown a significant increase in survival rate.

Scope

The report provides information on the key drivers and challenges of the GBM market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) GBM market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as angiogenic inhibitors, VEGF inhibitors, tyrosine kinase inhibitors, gene therapy, anti-mitotic agents, stem cell therapy.
- Analysis of the current and future competition in the global GBM market. Key market players covered are Hoffmann-La Roche Ltd, Merck, Eli Lilly, Ark Therapeutics and Antisense Pharma.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the GBM therapeutics market.
- Analysis of key recent licensing and partnership agreements in GBM market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global GBM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global GBM market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global GBM market landscape? – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Glioblastoma Multiforme (GBM) Therapeutics Introduction 7
2.1 Disease Overview 7
2.1.1 Classification of GBM 8
2.2 Epidemiology 9
2.3 Etiology and Pathophysiology 10
2.3.1 Environmental Factors 10
2.3.2 Genetic Factors 10
2.4 Symptoms 11
2.5 Prognosis 11
2.5.1 Tumor Size and Location 11
2.5.2 Treatment 11
2.5.3 Age 11
2.5.4 Karnofsky Performance Score (KPS) 11
2.6 Diagnosis 11
2.6.1 Neuroimaging Studies 11
2.6.2 Histology 12
2.7 Survival Rate 13
2.8 Treatment and Management Pattern 13
2.8.1 Surgery 14
2.8.2 Radiation Therapy (RT) 14
2.8.3 Chemotherapy 14
2.8.4 Targeted Therapy 14
2.9 GlobalData Pipeline Report Guidance 15
3 GBM Therapeutics: Market Characterization 16
3.1 GBM Therapeutics Market Size (2005-2010) – Global 16
3.2 GBM Therapeutics Market Forecast (2010-2018) – Global 17
3.3 GBM Therapeutics Market Size (2005-2010) – The US 18
3.4 GBM Therapeutics Market Forecast (2010-2018) – The US 19
3.5 GBM Therapeutics Market Size (2005-2010) – The UK 20
3.6 GBM Therapeutics Market Forecast (2010-2018) – The UK 21
3.7 GBM Therapeutics Market Size (2005-2010) – France 22
3.8 GBM Therapeutics Market Forecast (2010-2018) – France 23
3.9 GBM Therapeutics Market Size (2005-2010) – Germany 24
3.10 GBM Therapeutics Market Forecast (2010-2018) – Germany 25
3.11 GBM Therapeutics Market Size (2005-2010) – Italy 26
3.12 GBM Therapeutics Market Forecast (2010-2018) – Italy 27
3.13 GBM Therapeutics Market Size (2005-2010) – Spain 28
3.14 GBM Therapeutics Market Forecast (2010-2018) – Spain 29
3.15 GBM Therapeutics Market Size (2005-2010) – Japan 30
3.16 GBM Therapeutics Market Forecast (2010-2018) – Japan 31
3.17 Drivers and Barriers 32
3.17.1 Drivers for GBM Therapeutics Market 32
3.17.2 Barriers for GBM Therapeutics Market 32
3.18 Key Events Impacting the Future Market 33
3.19 Opportunity and Unmet Need 33
3.19.1 Unmet Need for Newly Diagnosed GBM Therapeutics 34
3.19.2 Unmet Need for Recurrent GBM Therapeutics 35
3.20 Key Takeaway 35
4 GBM Therapeutics Market – Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Product Profile for the Major Marketed Products in GBM Therapeutics Market 37
4.3.1 Temodar (temozolomide, TMZ) 37
4.3.2 Gliadel (carmustine implant) 39
4.3.3 Avastin (bevacizumab) 41
4.4 Key Takeaway 43
5 GBM Therapeutics: Pipeline Assessment 44
5.1 Overview 44
5.2 Strategic Pipeline Assessment 44
5.3 Pipeline by Phases of Development 45
5.3.1 GBM Therapeutics-Phase III Pipeline 45
5.3.2 GBM Therapeutics - Phase II Pipeline 46
5.3.3 GBM Therapeutics-Phase I/II Pipeline 47
5.3.4 GBM Therapeutics - Phase I Pipeline 48
5.3.5 GBM Therapeutics - Pre-Clinical Pipeline 49
5.3.6 GBM Therapeutics - Discovery Pipeline 49
5.4 GBM Therapeutics - Pipeline by Mechanism of Action 50
5.5 Technology Trends Analytic Framework 52
5.6 Promising Drugs under Clinical Development 54
5.7 Profile for Promising Drugs 54
5.7.1 Cerepro (sitimagene ceradenovec) 54
5.7.2 Cilengitide (EMD 121974) 55
5.7.3 Enzastaurin (LY317615) 56
5.7.4 Immuncell-LC 57
5.7.5 Trabedersen 58
5.8 Key Takeaway 58
6 GBM Therapeutics: Clinical Trials Mapping 59
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 59
6.2 Clinical Trials by Phase 60
6.3 Clinical Trials by Trial Status 61
6.4 Prominent Sponsors 62
6.5 Top Companies Participating in Therapeutics Clinical Trials 64
7 GBM Therapeutics: Strategic Assessment 65
7.1 Future Market Competition Scenario 65
8 GBM Therapeutics: Future Players 67
8.1 Introduction 67
8.2 Company Profiles 68
8.2.1 Hoffmann-La Roche Ltd 68
8.2.2 Merck & Co 71
8.2.3 Eli Lilly and Company 72
8.2.4 Ark Therapeutics Group 73
8.2.5 Antisense Pharma GmBH 74
8.2.6 Innocell Corporation 75
8.3 Other Companies in GBM Therapeutics Market 76
9 GBM Therapeutics: Licensing and Partnership Deals 79
10 Appendix 81
10.1 Market Definitions 81
10.2 Abbreviations 81
10.3 Methodology 82
10.3.1 Coverage 83
10.3.2 Secondary Research 83
10.3.3 Forecasting 83
10.3.4 Primary Research 86
10.3.5 Expert Panel Validation 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Bibliography 87